Applications for supplemental funding to support faculty negatively impacted by the COVID-19 pandemic are due by July 19, 2021
The SOM Office of Research would like to support SOM faculty who have been negatively impacted by the COVID-19 pandemic by providing supplemental funding of up to $20K per faculty investigator to support their research programs.
All faculty, including junior physician scientist faculty on fellowships or faculty on time-limited research awards are welcome to apply. However, priority will be given to early-career faculty in the first 5 years of their faculty appointment.
Please review the RFA linked here for detailed information about eligibility, required materials, and application process.
Applications must be submitted byJuly 19, 2021. Applications and questions can be sent to OoR_Submissions@med.unc.edu .
Christine Lentz, a Morrison & Foerster summer associate in our San Diego office,contributed to the writing of this article.
The outbreak of the COVID-19 pandemic in 2020 spurred rapid medical and technological innovation, leading to new medicines and devices designed in response to the virus. Under the traditional U.S. Food and Drug Administration (FDA) process, approval for these products could take months, if not yearstime many Americans did not have. Fortunately, the FDA had a secret weapon in the fight against COVID-19: emergency use authorizations (EUAs). In April 2020, we reported on the FDAs use of EUAs in the early months of the pandemic. Now, over one year later, we revisit the topic of EUAs to highlight the role they have played in pandemic responsiveness and explain what to expect going forward.
Congress first established the FDAs power to issue EUAs through the Project Bioshield Act of 2004. Generally speaking, EUAs enable the FDA to authorize unapproved products (or unapproved uses of approved products) for temporary use as emergency medical countermeasures against threats to public health and safety. From 2004 until recently, the FDA seldom issued EUAs; across the Zika, Ebola, MERS Coronavirus, H1N1/Swine flu, and Anthrax crises, the FDA issued EUAs for only a few dozen products combined.
The COVID-19 pandemic, however, led to the issuance of over 600 EUAs, including authorizations for three vaccines and ten drug and biological therapeutic products, as well as a wide range of personal protective equipment, in vitro diagnostics, ventilators, and more. Among these authorizations, the FDA responded to the testing and supply shortages prevalent at the start of the pandemic by issuing several umbrella EUAs for larger categories of devicese.g., Surgical Masks and Independently Validated Serology Tests for SARS-CoV-2which allowed those products on the market without individual review.
Several treatments for mild-to-moderate COVID-19 were authorized for emergency use, such as Gileads remdesivir, GlaxoSmithKlines Sotrovimab, Eli Lillys Bamlanivimab and Etesevimab, and Regenerons REGEN-COV (Casirivimab and Imdevimab). In addition, Fresenius Kabi received an EUA for its Propoven 2% Emulsion IV, which maintains sedation in patients requiring mechanical ventilation in an intensive care setting. Baxter Healthcare received authorization for its REGIOCIT replacement solutionfor adults treated with continuous renal replacement therapy in a critical care setting during the COVID-19 pandemic.
EUAs remain in effect until the circumstances justifying the authorization of emergency use during the pandemic end, the FDA revokes the EUA to protect public health or safety, or the FDA approves a marketing application for the product/use. To determine whether products temporarily authorized under EUAs remain necessary, the FDA periodically reviews the circumstances and appropriateness of existing authorizations, particularly the status of product approval. If the sponsor is not actively working toward approval, licensure, or clearance, the FDA may consider terminating the EUA. If an EUA remains in effect for more than one year, the FDA must provide the sponsor with a written explanation of obstacles to approval and specific actions to overcome them.[1]
During the current pandemic, the FDA has revoked, for a variety of reasons, three of its umbrella EUAs and several individual EUAs. One typical explanation for revocation is that when the FDA approves a product, it renders any prior EUA redundant. For example, the FDA revoked the corresponding EUA upon approving Gileads Veklury (remdesivir) for use in adults and certain pediatric patients.
Other times, however, the FDA revokes EUAs after learning that products are not completely effective or safe for use. Recent EUA revocations include reported adverse effects (Chloroquine phosphate and hydroxychloroquine sulfate); poor clinical performance (Chembios DPP COVID-19 IgM/IgG System); decreased effectiveness (Autobios Anti-SARS-CoV-2 Rapid Test; NovaSteriliss Nova2200 for Decontaminating Compatible N95 Respirators); increased viral variant resistance (Eli Lillys Bamlanivimab); and/or excessive risk-benefit ratio.
As the pandemic has evolved, so have public health needs and FDA priorities, which in turn have resulted in the discontinuation and de-prioritization of EUA application review for certain COVID-19 products.
For example, according to recent guidance (May 2021), the FDA may decline to review or process new EUA requests for COVID-19 vaccines, unless those developers have previously engaged with the Agency on the development of their manufacturing process and clinical trials program. If a developer has already received feedback from the FDA, its EUA request is more likely to contain comprehensive data and information that meet authorization issuance requirements, whereas quality and data in new applications may prove difficult to verify.
In addition to de-prioritizing new COVID-19 vaccine EUA submissions, the FDA no longer reviews requests nor adds new respirator models to the umbrella emergency use authorizations for Non-NIOSH-Approved Disposable Filtering Facepiece Respirators Manufactured in China (as of Oct. 15, 2020) orImported, Non-NIOSH-Approved Disposable Filtering Facepiece Respirators (as of Mar. 24, 2021). Respirator manufacturers who are not listed under the existing EUAs may submit a separate EUA request; however, the FDA does not encourage such submissions, as there is decreased demand for those devices.
Given the countrys continued recovery from the COVID-19 pandemic, we can likely expect additional classes of products to become deprioritized or ineligible for EUA. For example, as the proportion of vaccinated citizens increases and hospitalization rates decrease, many of the medical devices the country had scrambled to make available over a year ago will become less critical.
Companies with current EUAs or those considering applying for emergency use of their products should consult legal counsel to ensure continuity of product marketing and commercialization when the COVID-19 public health emergency is ended and/or EUAs are no longer effective.
Unless FDA announces a transitional policy for EUAs, manufacturers should assume they will need to receive full approval or clearance from the FDA to continue marketing their products after the public health emergency ends. For example, several Zika- and Ebola-related tests with emergency use authorizations received market clearance before the declared end of their respective emergencies. In October 2020, the FDA approved Inmazeb, the first treatment for Ebola Virus in the United States. To date, Pfizer-BioNTech and Moderna have submitted BLAs for their mRNA vaccines, along with requests for Priority Review to accelerate the approval process, while simultaneously expanding their EUAs.
The FDA encourages sponsors of EUA products to follow up EUA issuance with an appropriate approval, biologics license application (BLA), or device premarket submissionsuch as 510(k), De Novo Classification Request, or Premarket Approvalso that authorized products can remain on the market with minimal interruption once the EUA is no longer in effect. The FDA further expects sponsors to include a plan for safety follow-up in their EUA requests, which will inform benefit-risk determinations in support of EUA continuation.
The FDA also expects manufacturers who receive an EUA to continue their clinical trials to obtain additional safety and effectiveness information and pursue approval. Once enough data is available, EUA holders should consider submitting applications for FDA approval, as the process can take several months. Legal counsel can assist sponsors in navigating applications to accelerate the approval process, e.g., for Fast Track, Priority Review, or Material Threat Medical Countermeasure Priority Review Vouchers. Although the Secretary of Health and Human Services (HHS) must provide sufficient advance notice to allow for the disposition of an unapproved product, and of any other provided information/labeling related to an unapproved use before an EUA declaration terminates, this can unnecessarily disrupt the commercialization of your COVID-19 products.
[1] 21 U.S.C. 360bbb-3.
[View source.]
The Heads of the World Bank Group, International Monetary Fund, World Health Organization, and World Trade Organization today convened for the first meeting of the Task Force on COVID-19 Vaccines, Therapeutics and Diagnostics for Developing Countries. They issued the following joint statement:
As many countries are struggling with new variants and a third wave of COVID-19 infections, accelerating access to vaccines becomes even more critical to ending the pandemic everywhere and achieving broad-based growth. We are deeply concerned about the limited vaccines, therapeutics, diagnostics, and support for deliveries available to developing countries. Urgent action is needed now to arrest the rising human toll due to the pandemic, and to halt further divergence in the economic recovery between advanced economies and the rest.
We have formed a Task Force, as a war room to help track, coordinate and advance delivery of COVID-19 health tools to developing countries and to mobilize relevant stakeholders and national leaders to remove critical roadblocksin support of the priorities set out by World Bank Group, IMF, WHO, and WTO including in the joint statements of June 1 and June 3, and in the IMF staffs $50 billion proposal.
At todays first meeting, we discussed the urgency of increasing supplies of vaccines, therapeutics, and diagnostics for developing countries. We also looked at practical and effective ways to track, coordinate and advance delivery of COVID-19 vaccines to developing countries.
As an urgent first step, we are calling on G20 countries to (1) embrace the target of at least 40 percent in every country by end-2021, and at least 60 percent by the first half of 2022, (2) share more vaccine doses now, including by ensuring at least 1 billion doses are shared with developing countries in 2021 starting immediately, (3) provide financing, including grants and concessional financing, to close the residual gaps, including for the ACT-Accelerator, and (4) remove all barriers to export of inputs and finished vaccines, and other barriers to supply chain operations.
In addition, to enhance transparency we agreed to compile data on dose requests (by type and quantity), contracts, deliveries (including through donations), and deployments of COVID-19 vaccines to low and middle-income countriesand make it available as part of a shared country-level dashboard. We also agreed to take steps to address hesitancy, and to coordinate efforts to address gaps in readiness, so countries are positioned to receive, deploy and administer vaccines.
Syringes with AstraZeneca vaccine against the coronavirus disease (COVID-19) are pictured in Laakso hospital in Helsinki, Finland March 11, 2021. Picture taken March 11, 2021. REUTERS/Essi Lehto
HELSINKI, June 30 (Reuters) - Finland's capital Helsinki will begin giving COVID-19 vaccines to children aged 12 to 15 who are at risk of contracting a severe coronavirus infection, the city said on Wednesday.
Organ transplants, cancers, immunological disorders and Down's syndrome are considered as among the risk factors, according to the Finnish Health Institute.
According to data collected by the European Centre for Disease Prevention and Control, 71.6% of the 5.5 million Finns have now received one vaccination dose and 22% two doses.
The Nordic nation has recorded 95,742 infections and 973 deaths due to COVID-19.
Reporting by Essi Lehto;Editing by Alison Williams
Our Standards: The Thomson Reuters Trust Principles.
The West Virginia Department of Health and Human Resources (DHHR) reports as of June 30, 2021, there have been 3,008,327 total confirmatory laboratory results received for COVID-19, with 164,041 total cases and 2,891 deaths.
DHHR has confirmed the deaths of a 79-year old female from Gilmer County, an 88-year old female from Wayne County, a 76-year old male from Berkeley County, an 84-year old female from Jefferson County, a 90-year old female from Wayne County, an 81-year old female from Mineral County, a 79-year old male from Wetzel County, a 65-year old female from Braxton County, a 54-year old male from Fayette County, a 94-year old female from Marshall County, a 76-year old female from Mercer County, and an 83-year old male from Kanawha County.
Eleven of the 12 deaths reported in todays dashboard report are a result of the Bureau for Public Healths continuing data reconciliation with the official death certificate. Seven of the eleven deaths were from April and May 2021, while four of the deaths occurred in September 2020 (1), October 2020 (2), and January 2021 (1).
We are saddened by the loss of more West Virginians and extend deepest condolences to these grieving families, said Bill J. Crouch, DHHR Cabinet Secretary. Lets continue taking every precaution we can to stop the spread of this disease, including scheduling a COVID-19 vaccination for yourself and all eligible family members.
CASES PER COUNTY: Barbour (1,514), Berkeley (12,838), Boone (2,178), Braxton (1,015), Brooke (2,247), Cabell (8,885), Calhoun (389), Clay (543), Doddridge (644), Fayette (3,554), Gilmer (886), Grant (1,315), Greenbrier (2,894), Hampshire (1,925), Hancock (2,844), Hardy (1,581), Harrison (6,193), Jackson (2,255), Jefferson (4,799), Kanawha (15,496), Lewis (1,287), Lincoln (1,606), Logan (3,294), Marion (4,653), Marshall (3,537), Mason (2,062), McDowell (1,614), Mercer (5,181), Mineral (2,980), Mingo (2,761), Monongalia (9,398), Monroe (1,223), Morgan (1,226), Nicholas (1,905), Ohio (4,314), Pendleton (725), Pleasants (958), Pocahontas (681), Preston (2,959), Putnam (5,330), Raleigh (7,091), Randolph (2,854), Ritchie (760), Roane (665), Summers (865), Taylor (1,280), Tucker (547), Tyler (746), Upshur (1,968), Wayne (3,179), Webster (544), Wetzel (1,390), Wirt (457), Wood (7,948), Wyoming (2,058).
Free pop-up COVID-19 testing is available today in Barbour, Berkeley, Doddridge, Jefferson, Lincoln, Morgan, Ritchie, Tyler/Wetzel, and Wayne counties.
Barbour County
9:00 AM 11:00 AM, Barbour County Health Department, 109 Wabash Avenue, Philippi, WV
1:00 PM 5:00 PM, Junior Volunteer Fire Department, 331 Row Avenue, Junior, WV
Berkeley County
10:00 AM 5:00 PM, 891 Auto Parts Place, Martinsburg, WV
Doddridge County
Jefferson County
10:00 AM 6:00 PM, Hollywood Casino, 750 Hollywood Drive, Charles Town, WV
Lincoln County
Morgan County
11:00 AM 4:00 PM, Valley Health War Memorial Hospital, 1 Health Way, Berkeley Springs, WV
Ritchie County
1:00 PM 4:00 PM, Ritchie Regional, 138 S Penn Avenue, Harrisville, WV
Tyler/Wetzel Counties
Wayne County
10:00 AM 2:00 PM, Wayne Community Center, 11580 Rt. 152, Wayne, WV
VladimirVoronkov, head of the UNOffice ofCounter-Terrorism(OCT),concludedtheSecond High-level Conferenceof Heads ofCounter-Terrorism,bysumming upfourof thestrategic challenges facing the worldtoday.
He underscored the need for inclusive, forward-looking, evidence-based approaches to build resilience, in the face of the ISIL legacy in Iraq and Syria;terrorist threats in Africa;tackling transnationalriskssparked by various forms of intolerance; and the need toupgradetechnology and know-how to counter the scourge.
Deliberations over the last few days have advanced the Secretary-Generals vision to promote a networked global counter-terrorism response, said Mr.Voronkov.
However, he added,while preparing fortomorrowsthreats,wealsoneed tochangetraditional tactics.
Noting that hate speech has become pervasive and self-reinforcing through algorithms and online echo chambers,hesaid that countering the spread of terrorist content online remains high on the agenda.
Upholding the rule of law and human rightsis imperativefor successfulcounter-terrorism efforts, he said.
We must preserve and defend these fundamental values and operating principles while we work together to prevent terrorists efforts to destabilize our Governments and societies, stressed the OCT chief, saying that his office wouldintegrategender and human rights policies into all of its programming.
He also maintained the need to continue efforts to deliver tailored, cost-effective capacity-building measures to sustain impact, including through UN field-based programmes.
As many Member States continue to face severe capacity challenges in battling terrorism, Mr.Voronkovpointed out that new technologies are adding a layer of complexity.
He maintained that solidarity is in everyones common interest and that the international community cannot afford to leave any country behind.
It is clear that a terrorist safe haven anywhere is a threat everywhere, spelled out the OCT chief.
As the Organization readies itself to mark the 15th anniversary of theUN Global Counter-terrorismStrategyto enhance national, regional and international efforts,the UN official said, we should take comfort that this Counter-Terrorism Week has reinvigorated support for multilateralism.
He describedsome path-breaking outcomesto be included in an upcomingresolution, whichincluded countering the use of new technologies for terrorist purposes;tackling attacks based on racism and other forms of intolerance;andrepatriating, reintegrating and rehabilitating children with links to foreign terrorist fighters.
In closing,Mr.Voronkovreassured the Member States of the UNs leadership and to support andlooked forward tothe first Global Congress of Victims of Terrorismscheduled forDecember, andforthethirdUNCounter-Terrorism Weekin June 2023.
Last modified on June 30, 2021
Dear Stanford community,
About 1,160 undergraduates moved into our residential halls earlier this month, and nearly half of them are first-year frosh who are living on campus for the first time. The fact that we are able to bring so many students back for the summer after such a difficult year is a testament to the hard work, dedication and flexibility across our community that are enabling more and more of us to return to campus for the first time in a long time.
The university continues to review public health guidance and conditions and adjust campus protocols, while continuing to mitigate risks associated with COVID-19. An important step occurred June 26, when the restricted-activity period for undergraduates ended and we implemented new guidance from Cal/OSHA, the states Division of Occupational Safety and Health.
Following up on our guidance after the Cal/OSHA decision was announced, we are writing to share updated information and additional steps we are taking to prepare for more normal times ahead while continuing to put a premium on health and safety measures. Much of this guidance centers on vaccinations and Health Check submissions, which are essential parts of our toolbox.
Vaccination status and Health Check submissions
Several changes will involve the process for reporting vaccination status on Health Check and help highlight information that reflects improving conditions within our community.
First, beginning July 1, faculty, staff and postdoctoral scholars who have (1) listed their vaccination date(s) and manufacturers in Health Check and (2) uploaded an image of their documentation on Health Check will no longer be required to make Health Check submissions when coming to campus (unless they become symptomatic or receive a positive COVID test result) or to undergo regular testing. The upload feature will become available in Health Check at 5 p.m. on July 1.
In the coming weeks, students will also have this option after submitting vaccine documentation through the VadenPatient portal.
Second, these two changes regarding vaccination status and related documentation for faculty, staff and postdoctoral scholars will take effect Sept. 9:
For now, testing continues to be required for students, regardless of vaccination status.
We encourage you to be vaccinated for COVID-19, and we thank you for continuing to follow safety guidelines. Click here for resources and links to vaccination providers.
Vaccination information on COVID dashboards
As we shared last week, the Stanford COVID dashboards began including data on vaccinated individuals June 28. The totals reflect submissions to Health Check in two categories: students and faculty, staff and postdoctoral scholars. Because submissions are required only for those coming to campus and voluntary for any others, the totals are somewhat lower than the actual number of vaccinated individuals in the Stanford community.
Already, the results are very encouraging. More than 90 percent of those making Health Check submissions report that they have been vaccinated for COVID-19. We continue to encourage vaccinations for community members and their loved ones. Click here for resources and links to vaccination providers.
Physical distancing and density
We have made further revisions based on the latest updates to state and federal regulations regarding physical distancing and density.
These rules no longer contain general requirements on minimum distancing between individuals or on COVID-related building or room density. As a result, physical distancing is not required, except for certain limited situations for unvaccinated individuals as described in our updated guidance.
Privacy
We are asking all members of the Stanford community to continue to be respectful of each others privacy. Our colleagues need to make certain decisions at their own pace and based on their own comfort levels.
Please keep in mind that Health Check, and the VadenPatient portal for students, are the only approved channels through which the university asks for vaccination status. As with any other personal medical or health issue, supervisors, faculty and other colleagues should not ask students or co-workers about their COVID-19 vaccination status.
Anyone who is concerned about the vaccination status of colleagues, students or others they encounter on campus may choose to continue wearing a face covering or participate in the universitys free optional testing program.
Looking ahead, the coming weeks and fall quarter promise to be an exciting, hopeful time for our community. Thank you for your patience and understanding, your willingness to adjust and, most of all, your efforts to keep one another safe.
Sincerely,Russell FurrAssociate Vice ProvostEnvironmental Health & Safety
We're making this important information available without a subscription as a public service. But we depend on reader support to do this work. Please consider supporting independent journalism in Alaska, at just $3.69 a week for an online subscription.
Alaska on Wednesday reported 86 new coronavirus infections identified over the last two days, plus three COVID-19-related deaths, according to the state Department of Health and Social Services. The health department now updates its coronavirus dashboard on Mondays, Wednesdays and Fridays.
The three deaths, which occurred recently, involved a woman from the Prince of Wales and Hyder Census Area in her 50s; a Wasilla man who was 80 or older; and an Anchorage man in his 70s.
In total, 370 Alaskans and seven nonresidents with COVID-19 have died since the pandemic reached the state last spring. Alaskas death rate per capita remains among the lowest in the country, though the states size, health care system and other factors complicate national comparisons.
Some areas of the state are starting to see a slight uptick in case rates, including the Yukon-Kuskokwim Delta, which is currently in the high alert category, and Anchorage, which this week moved to the intermediate alert level. However, the states overall alert level remains low. Health officials continue to encourage Alaskans to get vaccinated against the virus, noting that the vaccines have been shown to be highly effective at preventing illness from the virus, including the more contagious variants.
By Wednesday, roughly 55% of the states population age 12 and older had received at least their first dose of the vaccine while 50% of residents 12 and older were considered fully vaccinated. Among all states, Alaska ranked No. 29 in the country for most vaccinated residents per capita.
There were 15 people with confirmed or suspected cases of COVID-19 hospitalized around the state, including five who were on ventilators.
The 79 newly reported cases among Alaska residents include 52 people from Anchorage, seven from Hooper Bay, seven from Wasilla, two from Juneau, two from Nome and one each from Eagle River, Ketchikan, Palmer, Sitka, Utqiagvik and Willow. Among smaller communities, there was one each from the Bethel Census Area, the Chugach Census Area and the northern Kenai Peninsula Borough.
Another seven cases were reported among nonresidents: six from Anchorage and one from Soldotna.
Of all the coronavirus tests completed in the state over the last week, 1.24% came back positive.
The COVID-19 pandemic has resulted in declines in cancer detection and surgical treatments, according to a study published in JNCI: The Journal of the National Cancer Institute. The investigators found that population-based cancer registries showed a 10.2% decline in real-time electronic pathology reports in 2020 compared to 2019.
The researchers observed declines across all age groups, including children under 18 years of age. Percentage declines were the highest for lung and colorectal cancers, with a decrease of 17.4% and 12.0%, respectively. Breast and prostate cancers were the next most serious declines, with percentage decreases of 9.0% and 5.8%, respectively.
We observed substantial declines in 2020 among cancers with effective screening tests, including breast and colorectal cancers, as well as across cancer sites and age groups without effective screening tests, including cancers among children and young adults, said Robin Yabroff, PhD, MBA, of the American Cancer Society, in a press release. Declines across cancer sites and age groups suggest that in addition to delays in cancer screening, there were also delays in routine well-child and primary care, evaluation of signs and symptoms, and treatment initiation for most cancers.
The study found that the patterns of decline seen in cancer care were similar to those seen in other fields of health care, with the greatest difference seen in April 2020 compared to April 2019. This decline in care aligns with the first peak in COVID-19 mortality rates in Georgia and Louisiana, and the declines in pathology reports seen in August, November, and December 2020 also coincided with COVID-19 mortality rate peaks. According to the investigators, the number of pathology reports across all of 2020 never consistently exceeded those in 2019 after these initial declines.
The findings suggest substantial delays in diagnosis and treatment services for cancers during the pandemic, and that ongoing evaluation can inform public health efforts to minimize any lasting adverse effects of the pandemic on cancer diagnosis, stage, treatment, and survival, the authors wrote. As data become available, evaluation of the effects of the pandemic on cancer stage at diagnosis and survival will be important, as will evaluation of racial/ethnic, socioeconomic, and geographic disparities in access to care and outcomes.
REFERENCE
Study finds adverse effects of COVID-19 pandemic on cancer detection and surgical treatments [news release]. EurekAlert; June 28, 2021. Accessed June 29, 2021. https://www.eurekalert.org/pub_releases/2021-06/acs-sfa062821.php
Soccer Football - Serie A - Juventus v Napoli - Allianz Stadium, Turin, Italy - April 7, 2021 Juventus' Cristiano Ronaldo celebrates after the match REUTERS/Massimo Pinca/File Photo
June 30 (Reuters) - Italian soccer club Juventus (JUVE.MI) plans to raise up to 400 million euros ($474 million) in a new share issue to offset the hit to its finances from the COVID-19 pandemic, it said on Wednesday.
The Serie A club put the cost of the pandemic at 320 million euros for the fiscal years between 2019 and 2022, due to stadiums remaining closed for extended periods of time amid COVID-19 restrictions.
Juventus also said it had appointed Maurizio Arrivabene as chief executive officer for football as part of a broader revamp of its sporting management structure.
Arrivabene, who already sits on Juventus' management board, was formerly at luxury sports car maker Ferrari (RACE.MI), which like the Turin-based club is controlled by Italy's Agnelli family.
The reorganisation comes after a failed attempt by Juventus and other top European clubs to set up a breakaway league in an effort to lift revenues.
Juventus, home to Portuguese star Cristiano Ronaldo, said in February it expected to end the 2020/2021 financial year in the red, after recording a first-half loss of 113 million euros.
The club's board said top shareholder Exor (EXOR.MI), the Agnelli's holding company, would back the proposed share issue to keep its 63.8% stake.
Confirming what sources told Reuters on Monday, Juventus said it had contacted lenders to evaluate setting up a bank consortium to guarantee the potential capital increase. read more
The Juventus board will make a final decision on the rights issue plan in September, ahead of a general shareholder meeting in October to approve 2020/2021 results.
($1 = 0.8439 euros)
Reporting by Silvia Recchimuzzi in Gdansk and Elvira Pollina in Milan Editing by Valentina Za and Mark Potter
Our Standards: The Thomson Reuters Trust Principles.
